Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.94 USD | +2.06% | +3.63% | -18.22% |
07:39pm | Bristol-Myers Squibb Says Breyanzi Studies Show 'Meaningful' Outcomes Across B-cell Malignancies | MT |
02:58pm | Bristol Myers: presents advances in lung cancer | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.22% | 83.29B | |
+42.79% | 739B | |
+32.34% | 598B | |
-5.57% | 353B | |
+17.75% | 318B | |
+3.76% | 285B | |
+16.47% | 240B | |
+9.26% | 210B | |
-5.07% | 206B | |
+6.74% | 164B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint